Related Experiment Video
Updated: Aug 24, 2025
14:04
Biosensor for Detection of Antibiotic Resistant Staphylococcus Bacteria
Published on: May 8, 2013
24.6K
Identification of Staphylococcus aureus Penicillin Binding Protein 4 (PBP4) Inhibitors
Mikaeel Young1, Danica J Walsh2, Elysia Masters3
1Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY 14642, USA.
Antibiotics (Basel, Switzerland)
|October 27, 2022
Summary
New research identifies potential PBP4 inhibitors to combat Methicillin-resistant Staphylococcus aureus (MRSA) infections. These compounds may reverse antibiotic resistance and prevent chronic bone infections, offering a dual therapeutic approach for MRSA and osteomyelitis.
Area of Science:
- Microbiology and Infectious Diseases
- Drug Discovery and Development
- Molecular Biology
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant global health threat, with resistance historically linked to the mecA gene.
- Emerging evidence highlights the crucial role of penicillin binding protein 4 (PBP4) in S. aureus methicillin resistance, particularly in community-acquired strains.
- PBP4 is also essential for S. aureus invasion and colonization of the bone osteocyte lacuno-canalicular network (OLCN), facilitating chronic osteomyelitis.
Purpose of the Study:
- To identify small molecules that inhibit Staphylococcus aureus PBP4.
- To explore the potential of PBP4 inhibitors as agents to reverse MRSA antibiotic resistance.
- To investigate PBP4 inhibitors as a strategy to prevent MRSA-induced chronic osteomyelitis.
Main Methods:
- A high-throughput screening of a 30,000-member small molecule library was employed to identify PBP4 inhibitors.
- Quantitative reverse transcriptase PCR and PBP4 binding assays were used to characterize inhibitor mechanisms (expression vs. function).
- Microfluidic-Silicon Membrane-Canalicular Arrays (µSiM-CA) were utilized to model OLCN invasion and assess inhibitor efficacy.
Main Results:
- Several putative S. aureus PBP4 inhibitors were identified through whole-cell screening.
- Compounds were differentiated based on their effect on PBP4 expression or protein function.
- The lead candidate, 9314848, at 6.25 µM, effectively reversed the PBP4-dependent MRSA phenotype and inhibited OLCN traversal.
Conclusions:
- PBP4 is a critical target for developing novel therapeutic strategies against MRSA.
- Identified PBP4 inhibitors demonstrate potential in both reversing antibiotic resistance and preventing chronic bone infections.
- These molecules represent promising candidates for further development as MRSA infection adjuvants or osteomyelitis prophylactics.
